TY - JOUR AU - Drossman, D. A. PY - 2006 DA - 2006// TI - The functional gastrointestinal disorders and the Rome III process JO - Gastroenterology VL - 130 UR - https://doi.org/10.1053/j.gastro.2006.03.008 DO - 10.1053/j.gastro.2006.03.008 ID - Drossman2006 ER - TY - JOUR AU - Sandler, R. S. PY - 1990 DA - 1990// TI - Epidemiology of irritable bowel syndrome in the United States JO - Gastroenterology VL - 99 UR - https://doi.org/10.1016/0016-5085(90)91023-Y DO - 10.1016/0016-5085(90)91023-Y ID - Sandler1990 ER - TY - JOUR AU - Gralnek, I. M. AU - Hays, R. D. AU - Kilbourne, A. AU - Naliboff, B. AU - Mayer, E. A. PY - 2000 DA - 2000// TI - The impact of irritable bowel syndrome on health-related quality of life JO - Gastroenterology VL - 119 UR - https://doi.org/10.1053/gast.2000.16484 DO - 10.1053/gast.2000.16484 ID - Gralnek2000 ER - TY - JOUR AU - Saito, Y. A. AU - Talley, N. J. AU - Melton, L. J. AU - Fett, S. AU - Zinsmeister, A. R. AU - Locke, G. R. PY - 2003 DA - 2003// TI - The effect of new diagnostic criteria for irritable bowel syndrome on community prevalence estimates JO - Neurogastroenterol Motil VL - 15 UR - https://doi.org/10.1046/j.1350-1925.2003.00441.x DO - 10.1046/j.1350-1925.2003.00441.x ID - Saito2003 ER - TY - JOUR AU - Kang, J. Y. PY - 2005 DA - 2005// TI - Systematic review: the influence of geography and ethnicity in irritable bowel syndrome JO - Aliment Pharmacol Ther VL - 21 UR - https://doi.org/10.1111/j.1365-2036.2005.02396.x DO - 10.1111/j.1365-2036.2005.02396.x ID - Kang2005 ER - TY - JOUR AU - Kanazawa, M. AU - Miwa, H. AU - Nakagawa, A. AU - Kosako, M. AU - Akiho, H. AU - Fukudo, S. PY - 2016 DA - 2016// TI - Abdominal bloating is the most bothersome symptom in irritable bowel syndrome with constipation (IBS-C): a large population-based Internet survey in Japan JO - BioPyschoSoc Med VL - 10 UR - https://doi.org/10.1186/s13030-016-0070-8 DO - 10.1186/s13030-016-0070-8 ID - Kanazawa2016 ER - TY - JOUR AU - Miwa, H. PY - 2008 DA - 2008// TI - Prevalence of irritable bowel syndrome in Japan: Internet survey uing Rome III criteria JO - Patients Prefer Adherence VL - 2 ID - Miwa2008 ER - TY - CHAP AU - Longstreth, G. F. AU - Thompson, W. G. AU - Chey, W. D. AU - Houghton, L. A. AU - Mearin, F. AU - Spiller, R. C. ED - Drossman, D. A. ED - Corazziari, E. PY - 2006 DA - 2006// TI - Functional bowel disorders BT - Rome III PB - Degnon Associates CY - McLean ID - Longstreth2006 ER - TY - JOUR AU - Spiller, R. AU - Aziz, Q. AU - Creed, F. AU - Emmanuel, A. AU - Houghton, L. AU - Hungin, P. PY - 2007 DA - 2007// TI - Guidelines on the irritable bowel syndrome: mechanisms and practical management JO - Gut VL - 56 UR - https://doi.org/10.1136/gut.2007.119446 DO - 10.1136/gut.2007.119446 ID - Spiller2007 ER - TY - JOUR AU - Whitehead, W. E. AU - Crowell, M. D. AU - Robinson, J. C. AU - Heller, B. R. AU - Schuster, M. M. PY - 1992 DA - 1992// TI - Effects of stressful life events on bowel symptoms: subjects with irritable bowel syndrome compared with subjects without bowel dysfunction JO - Gut VL - 33 UR - https://doi.org/10.1136/gut.33.6.825 DO - 10.1136/gut.33.6.825 ID - Whitehead1992 ER - TY - JOUR AU - Kanazawa, M. AU - Palsson, O. S. AU - Thiwan, S. I. AU - Tumer, M. J. AU - Tilburg, M. A. AU - Gangarosa, L. M. PY - 2008 DA - 2008// TI - Contributions of pain sensitivity and colonic motility to IBS symptom severity and predominant bowel habits JO - Am J Gastroenterol VL - 103 UR - https://doi.org/10.1111/j.1572-0241.2008.02066.x DO - 10.1111/j.1572-0241.2008.02066.x ID - Kanazawa2008 ER - TY - JOUR AU - Dunlop, S. P. AU - Coleman, N. S. AU - Blackshaw, E. AU - Perkins, A. C. AU - Singh, G. AU - Marsden, C. A. PY - 2005 DA - 2005// TI - Abnormalities of 5-hydroxytryptamine metabolism in irritable bowel syndrome JO - Clin Gastroenterol Hepatol VL - 3 UR - https://doi.org/10.1016/S1542-3565(04)00726-8 DO - 10.1016/S1542-3565(04)00726-8 ID - Dunlop2005 ER - TY - JOUR AU - Miyata, K. AU - Kamato, T. AU - Nishida, A. AU - Ito, H. AU - Katsuyama, Y. AU - Iwai, A. PY - 1991 DA - 1991// TI - Pharmacologic profile of (R)-5-[(1-methyl-3-indolyl)carbonyl]-4,5,6,7-tetrahydro-1H-benzimidazole hydrochloride (YM060), a potent and selective 5-hydroxytryptamine3 receptor antagonist, and its enantiomer in the isolated tissue JO - J Pharmacol Exp Ther VL - 259 ID - Miyata1991 ER - TY - JOUR AU - Miyata, K. AU - Kamato, T. AU - Nishida, A. AU - Ito, H. AU - Yuki, H. AU - Yamano, M. PY - 1992 DA - 1992// TI - Role of the serotonin3 receptor in stress-induced defecation JO - J Pharmacol Exp Ther VL - 261 ID - Miyata1992 ER - TY - JOUR AU - Miyata, K. AU - Ito, H. AU - Fukudo, S. PY - 1998 DA - 1998// TI - Involvement of the 5-HT3 receptor in CRH-induced defecation in rats JO - Am J Physiol VL - 274 ID - Miyata1998 ER - TY - JOUR AU - Miyata, K. AU - Yamano, M. AU - Kamato, T. AU - Akuzawa, S. PY - 1995 DA - 1995// TI - Effect of serotonin (5-HT)3-receptor antagonists YM060, YM114 (KAE-393), ondansetron and granisetron on 5-HT4 receptors and gastric emptying in rodents JO - Jpn J Pharmacol VL - 69 UR - https://doi.org/10.1254/jjp.69.205 DO - 10.1254/jjp.69.205 ID - Miyata1995 ER - TY - JOUR AU - Matsueda, K. AU - Harasawa, S. AU - Hongo, M. AU - Hiwatashi, N. AU - Sasaki, D. PY - 2008 DA - 2008// TI - A phase II trial of the novel serotonin type 3 receptor antagonist ramosetron in Japanese male and female patients with diarrhea-predominant irritable bowel syndrome JO - Digestion VL - 77 UR - https://doi.org/10.1159/000150632 DO - 10.1159/000150632 ID - Matsueda2008 ER - TY - JOUR AU - Matsueda, K. AU - Harasawa, S. AU - Hongo, M. AU - Hiwatashi, N. AU - Sasaki, D. PY - 2008 DA - 2008// TI - A randomized, double-blind, placebo-controlled clinical trial of the effectiveness of the novel serotonin type 3 receptor antagonist ramosetron in both male and female Japanese patients with diarrhea-predominant irritable bowel syndrome JO - Scand J Gastroenterol VL - 43 UR - https://doi.org/10.1080/00365520802240255 DO - 10.1080/00365520802240255 ID - Matsueda2008 ER - TY - JOUR AU - Fukudo, S. AU - Matsueda, K. AU - Haruma, K. AU - Ida, M. AU - Hayase, H. AU - Akiho, H. PY - 2017 DA - 2017// TI - Optimal dose of ramosetron in female patients with irritable bowel syndrome with diarrhea: a randomized, placebo-controlled phase II trial JO - Neurogastroenterol Motil ID - Fukudo2017 ER - TY - JOUR AU - Fukudo, S. AU - Kinoshita, Y. AU - Okumura, T. AU - Ida, M. AU - Akiho, H. AU - Nakashima, Y. PY - 2016 DA - 2016// TI - Ramosetron reduces symptoms of irritable bowel syndrome with diarrhea and improves quality of life in women JO - Gastroenterology VL - 150 UR - https://doi.org/10.1053/j.gastro.2015.10.047 DO - 10.1053/j.gastro.2015.10.047 ID - Fukudo2016 ER - TY - JOUR AU - Fukudo, S. AU - Kinoshita, Y. AU - Okumura, T. AU - Ida, M. AU - Hayashi, K. AU - Akiho, H. PY - 2016 DA - 2016// TI - Effect of ramosetron in female patients with irritable bowel syndrome with diarrhea: a phase III long-term study JO - J Gastroenterol VL - 9 UR - https://doi.org/10.1007/s00535-016-1165-5 DO - 10.1007/s00535-016-1165-5 ID - Fukudo2016 ER - TY - JOUR AU - Hirata, T. AU - Keto, Y. AU - Nakata, M. AU - Takeuchi, A. AU - Funatsu, T. AU - Akuzawa, S. PY - 2008 DA - 2008// TI - Effects of serotonin 5-HT3 receptor antagonists on stress-induced colonic hyperalgesia and diarrhoea in rats: a comparative study with opioid receptor agonists, a muscarinic receptor antagonist and a synthetic polymer JO - Neurogastroenterol Motil VL - 20 UR - https://doi.org/10.1111/j.1365-2982.2007.01069.x DO - 10.1111/j.1365-2982.2007.01069.x ID - Hirata2008 ER - TY - STD TI - Veldhuyzen van Zanten SJ, Talley NJ, et al. Design of treatment trial for the functional gastrointestinal disorders. In: Drossman DA et al., editors. Rome II –The functional gastrointestinal disorders. McLean: Degnon Associates; 2000. p. 577–622. ID - ref23 ER - TY - STD TI - Ida M, Nishida A, Akiho H, Nakashima Y, Matsueda K Fukudo S, Evaluation of the irritable bowel syndrome severity index in Japanese male patients with irritable bowel syndrome with diarrhea. BioPyschoSocial Medicine. 2017. doi:10.1186/s13030-017-0092-x. ID - ref24 ER - TY - JOUR AU - Longstreth, G. F. AU - Thompson, W. G. AU - Chey, W. D. AU - Houghton, L. A. AU - Mearin, F. AU - Spiller, R. C. PY - 2006 DA - 2006// TI - Functional bowel disorders JO - Gastroenterology VL - 130 UR - https://doi.org/10.1053/j.gastro.2005.11.061 DO - 10.1053/j.gastro.2005.11.061 ID - Longstreth2006 ER - TY - JOUR AU - Fukudo, S. AU - Ida, M. AU - Akiho, H. AU - Nakashima, Y. AU - Matsueda, K. PY - 2014 DA - 2014// TI - Effect of ramosetron on stool consistency in male patients with irritable bowel syndrome with diarrhea JO - Clin Gastroenterol Hepatol VL - 12 UR - https://doi.org/10.1016/j.cgh.2013.11.024 DO - 10.1016/j.cgh.2013.11.024 ID - Fukudo2014 ER - TY - JOUR AU - Spiegel, B. M. AU - Bolus, R. AU - Agarwal, N. AU - Sayuk, G. AU - Harris, L. A. AU - Lucak, S. PY - 2010 DA - 2010// TI - Measuring symptoms in the irritable bowel syndrome: development of a framework for clinical trials JO - Aliment Pharmacol Ther VL - 32 UR - https://doi.org/10.1111/j.1365-2036.2010.04464.x DO - 10.1111/j.1365-2036.2010.04464.x ID - Spiegel2010 ER - TY - JOUR AU - Mangel, A. W. AU - Northcutt, A. R. PY - 1999 DA - 1999// TI - Review article: the safety and efficacy of alosetron, a 5-HT3 receptor antagonist, in female irritable bowel syndrome patients JO - Aliment Pharmacol Ther VL - 13 UR - https://doi.org/10.1046/j.1365-2036.1999.00010.x DO - 10.1046/j.1365-2036.1999.00010.x ID - Mangel1999 ER - TY - JOUR AU - Chang, L. AU - Ameen, V. Z. AU - Dukes, G. E. AU - McSorley, D. J. AU - Carter, E. G. AU - Mayer, E. A. PY - 2005 DA - 2005// TI - A dose-rating, phase II study of the efficacy and safety of alosetron in men with diarrhea-predominant IBS JO - Am J Gastroenterol VL - 100 UR - https://doi.org/10.1111/j.1572-0241.2005.40365.x DO - 10.1111/j.1572-0241.2005.40365.x ID - Chang2005 ER - TY - JOUR AU - O’Donnell, L. J. AU - Virjee, J. AU - Heaton, K. W. PY - 1990 DA - 1990// TI - Detection of pseudodiarrhoea by simple clinical assessment of intestinal transit rate JO - BMJ VL - 300 UR - https://doi.org/10.1136/bmj.300.6722.439 DO - 10.1136/bmj.300.6722.439 ID - O’Donnell1990 ER - TY - JOUR AU - Fukudo, S. AU - Kaneko, H. AU - Akiho, H. AU - Inamori, M. AU - Endo, Y. AU - Okumura, T. PY - 2015 DA - 2015// TI - Evidence-based clinical practice guidelines for irritable bowel syndrome JO - J Gastroenterol VL - 50 UR - https://doi.org/10.1007/s00535-014-1017-0 DO - 10.1007/s00535-014-1017-0 ID - Fukudo2015 ER - TY - JOUR AU - Thompson, W. G. AU - Heaton, K. W. AU - Smyth, G. T. AU - Symth, C. PY - 2000 DA - 2000// TI - Irritable bowel syndrome in general practice: prevalence, characteristics, and referral JO - Gut VL - 46 UR - https://doi.org/10.1136/gut.46.1.78 DO - 10.1136/gut.46.1.78 ID - Thompson2000 ER - TY - JOUR AU - Koloski, N. A. AU - Jones, M. AU - Kalantar, J. AU - Weltman, M. AU - Zaquirre, J. AU - Talley, N. J. PY - 2012 DA - 2012// TI - The brain-gut pathways in functional gastrointestinal disorders is bidirectional: a 12-year prospective population-based study JO - Gut VL - 61 UR - https://doi.org/10.1136/gutjnl-2011-300474 DO - 10.1136/gutjnl-2011-300474 ID - Koloski2012 ER - TY - JOUR AU - Pimentel, M. AU - Talley, N. J. AU - Quigley, E. M. AU - Hani, A. AU - Sharara, A. AU - Mahachai, V. PY - 2013 DA - 2013// TI - Report from the multinational irritable bowel syndrome initiative 2012 JO - Gastroenterology ID - Pimentel2013 ER - TY - JOUR AU - Kux, L. PY - 2012 DA - 2012// TI - Department of Health and Human Services, Food and Drug Administration [docket no. FDA–2012–D–0146]: guidance for industry on irritable bowel syndrome—clinical evaluation of drugs for treatment: availability JO - Fed Regist VL - 77 ID - Kux2012 ER - TY - JOUR AU - Marquis, P. AU - Lasch, K. E. AU - Delgado-Herrera, L. AU - Kothari, S. AU - Lembo, A. AU - Lademacher, C. PY - 2014 DA - 2014// TI - Qualitative development of a patient-reported outcome symptom measure in diarrhea-predominant irritable bowel syndrome JO - Clin Transl Gastroenterol ID - Marquis2014 ER - TY - STD TI - U.S. Department of Health and Human Services. Guidance for industry patient-reported outcome measures: Use in medical product development to support labeling claims. 2009. http://www.fda.gov/downloads/Drugs/Guidances/UCM193282.pdf. UR - http://www.fda.gov/downloads/Drugs/Guidances/UCM193282.pdf ID - ref37 ER -